We're more than a slogan, our work speaks for itself.
Founded in 2001, Richmond Pharmacology is currently one of fifteen MHRA accredited phase one units in the UK.
As renowned pioneers in practical Adaptive Study Design, we actively work to maximise return on our sponsors’ clinical trials.
Patients and network staff talk about their experiences of being involved in clinical research.
Join Professor John Camm for his discussion on Atrial Fibrillation.
Richmond Pharmacology discusses the risks and appeal of participating in drug trials on the BBC Breakfast News show, featured Tuesday 22 May.
Professor John Camm discusses the two newest antiarrhythmic drugs dronedarone (Multaq®), which is now approved in the US and Europe for atrial fibrillation, and vernakalant, which is a year or two away.
Now's your chance to watch us work - check out the video below for a snapshot of our bustling team in action.
More about our Specialist Services
Significant work has been undertaken to push forward the launch of a new apprentice scheme aimed at raising theRead more ›
Richmond Pharmacology’s Research Director Dr Radivoj Arezina has written a piece for the July edition of GMP ReviewRead more ›
Richmond Pharmacology is delighted to confirm an upcoming event alongside the Department of International Trade inRead more ›